Medicenna Therapeutics Corp. (MDNA.TO)
CAD 1.75
(-2.23%)
CAD 1.75
(-2.23%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -18.67 Million CAD | 13.72% |
| 2022 | -16.29 Million CAD | 2.8% |
| 2021 | -22.53 Million CAD | -29.83% |
| 2020 | -17.24 Million CAD | -109.16% |
| 2019 | -8.26 Million CAD | -72.97% |
| 2018 | -4.7 Million CAD | 35.7% |
| 2017 | -7.45 Million CAD | 3.76% |
| 2016 | -7.62 Million CAD | -539.18% |
| 2015 | -1.19 Million CAD | -44.65% |
| 2014 | -828.38 Thousand CAD | -21879.01% |
| 2013 | - CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -4.03 Million CAD | -0.88% |
| 2023 FY | - CAD | 13.73% |
| 2023 Q3 | -4.77 Million CAD | 29.86% |
| 2023 Q1 | -5.7 Million CAD | -235.23% |
| 2023 Q2 | -6.8 Million CAD | -19.25% |
| 2023 Q4 | -4 Million CAD | 16.23% |
| 2022 Q2 | -7.1 Million CAD | -58.7% |
| 2022 Q4 | -1.7 Million CAD | 79.63% |
| 2022 Q3 | -8.35 Million CAD | -17.7% |
| 2022 Q1 | -4.47 Million CAD | -47.64% |
| 2022 FY | - CAD | 2.8% |
| 2021 Q4 | -3.03 Million CAD | 38.9% |
| 2021 FY | - CAD | -29.83% |
| 2021 Q1 | -6.01 Million CAD | -7.99% |
| 2021 Q2 | -8.25 Million CAD | -37.32% |
| 2021 Q3 | -4.96 Million CAD | 39.92% |
| 2020 Q1 | -2.58 Million CAD | 1.79% |
| 2020 FY | - CAD | -109.16% |
| 2020 Q2 | -3.84 Million CAD | -48.83% |
| 2020 Q4 | -5.56 Million CAD | -8.07% |
| 2020 Q3 | -5.15 Million CAD | -34.02% |
| 2019 Q4 | -2.62 Million CAD | -9.04% |
| 2019 Q3 | -2.41 Million CAD | -28.82% |
| 2019 Q2 | -1.87 Million CAD | -45.8% |
| 2019 Q1 | -1.28 Million CAD | -16.72% |
| 2019 FY | - CAD | -72.97% |
| 2018 FY | - CAD | 35.7% |
| 2018 Q4 | -1.1 Million CAD | 35.34% |
| 2018 Q3 | -1.7 Million CAD | -93.57% |
| 2018 Q2 | -878.98 Thousand CAD | 17.0% |
| 2018 Q1 | -1.05 Million CAD | 18.32% |
| 2017 Q1 | -2.22 Million CAD | 48.88% |
| 2017 Q4 | -1.29 Million CAD | 40.21% |
| 2017 FY | - CAD | 3.76% |
| 2017 Q2 | -1.68 Million CAD | 24.29% |
| 2017 Q3 | -2.16 Million CAD | -28.82% |
| 2016 Q1 | -10.65 Thousand CAD | -20.73% |
| 2016 FY | - CAD | -539.18% |
| 2016 Q3 | -2.21 Million CAD | -35994.88% |
| 2016 Q4 | -4.34 Million CAD | -96.66% |
| 2016 Q2 | -6127.00 CAD | 42.51% |
| 2015 Q2 | -157.11 Thousand CAD | -964.29% |
| 2015 Q4 | -8827.00 CAD | 98.44% |
| 2015 Q3 | -565.6 Thousand CAD | -260.0% |
| 2015 FY | - CAD | -44.65% |
| 2015 Q1 | -14.76 Thousand CAD | 0.0% |
| 2014 FY | - CAD | -21879.01% |
| 2013 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Appili Therapeutics Inc. | -2.09 Million CAD | -790.584% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | 50.074% |
| Helix BioPharma Corp. | -9.38 Million CAD | -98.85% |
| Microbix Biosystems Inc. | 1.95 Million CAD | 1053.98% |
| Satellos Bioscience Inc. | -15.7 Million CAD | -18.879% |
| Oncolytics Biotech Inc. | -33.71 Million CAD | 44.616% |
| Sernova Corp. | -40.19 Million CAD | 53.549% |